Present status of antileishmanial vaccines

Molecular and Cellular Biochemistry

Volumn 253, Issue 1-2, 2003, Pages 199-205

  Ghosh, Monidipa ^a   Bandyopadhyay, Santu ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Dendritic cell; Immunity; Vaccination; Visceral leishmaniasis

Indexed keywords

ANTILEISHMANIAL AGENT; DNA VACCINE; GAMMA INTERFERON; INACTIVATED VACCINE; INTERLEUKIN 12; LEISHMANIA VACCINE; LIVE VACCINE; NAKED DNA; SYNTHETIC PEPTIDE;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; IMMUNOPROPHYLAXIS; LEISHMANIA DONOVANI; LEISHMANIASIS; NONHUMAN; PROTOZOON; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIPROTOZOAL AGENTS; CYTOKINES; DENDRITIC CELLS; DRUG RESISTANCE; HUMANS; LEISHMANIA; LEISHMANIASIS; PEPTIDES; PROTOZOAN VACCINES;

LEISHMANIA DONOVANI; PROTOZOA;

EID: 0142212365     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026047429604     Document Type: Review

References (61)

1. WHO Report on Global Surveillance of Epidemic-prone infectious Diseases, 2000
2. Modabber F: TDR Eleventh Programme Report 8
3. Kemp K: Cytokine producing T cell subsets in human leishmaniasis. Arch Immunol Ther Exp 48: 173-176, 2000
4. Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AMY, Moller T, Kharazmi A, Theander TG: Immunopathology of post kala-azar dermal leishmaniasis: T cell phenotypes and cytokine profile. J Pathol 189: 615-622, 1999
5. Kaye PM, Curry AJ, Blackwell JM: Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146: 2763-2770, 1991
6. Satoskar A, Bluethmann H, Alexander J: Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 63: 4894-4899, 1995
7. Kathrryn, JM, Greg M: Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Imuunol 152: 2930, 1994
8. Green SJ, Meltzer MS, Hibbs Jr. JB, Nacy CA: Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 144: 278-286, 1990
9. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, Reed SG: Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism. Science 257: 545-548, 1992
10. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A: Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesion and those recovered from infection. Infect Immun 68: 1760-1764, 2000
11. Kemp M, Handman E, Kemp K, Ismail A, Mustafa MD, Kordofani AY, Bendtzen K, Kharazmi A, Theander TG: The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L-major. FEMS Immunol Med Microbiol 20: 209-218, 1998
12. Bogdan C: The multiplex function of nitric oxide in (auto) immunity. J Exp Med 187: 1361-1365, 1998
13. Levick MP, Tetaud E, Fairlamb AN, Blackwell JM: Identification and characterisation of a functional peroxidoxin from Leishmania major. Mol Biochem Parasitol 96: 125-137, 1998
14. + T cell response. J Exp Med 181: 961-971, 1995
15. Murray HW, Delph-Etienne S: Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 68: 288-292, 2000
16. Vouldoukis I, Riveros-Moreno V, Dugas B, Quaaz F, Becherel P, Debre P, Moncada S, Mossalayi MD: The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc RII/CD23 surface antigen. Proc Natl Acad Sci USA 92: 7804-7808, 1995
17. Cote-Sierra J, Bredan A, Toldos CM, Stijlemans B, Brys L, Cornelis P: Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect Immun 70: 240-248, 2002
18. Nashleanas M, Kanaly S, Scott P: Control of Leishmania major infection in mice lacking TNF receptors. J Immunol 160: 5506-5513, 1998
19. Padigel UM, Perrin PJ, Farrell JP: The development of a Th1-Type response and resistance to Leishmania major infection in the absence of CD40-CD40L co-stimulation. J Immunol 167: 5874-5879, 2001
20. + T cell. Nat Med 6: 1154-1159, 2000
21. Mc Rae BL, Beilfuss BA, Vanseventer GA: IFN-β differentially regulates CD40-induced cytokine secretion by human dendritic cells. J Immunol 164: 23-28, 2000
22. Huang FP, Xu D, Esfandiari EO, Sands W, Wei XQ, Liew FY: Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J Immunol 160: 4143-4147, 1998b
23. Desbarats J, Stone JE, Lin L, Zakeri ZF, Davis GS, Pfeiffer LM, Titus RG, Newell MK: Rapid early onset lymphocyte cell death in mice resistant, but not susceptible to Leishmania major infection. Apoptosis 5: 189-196, 2000
24. Sarih M, Souvannavong V, Adam A: Nitric oxide synthase induces macrophage death by apoptosis. Biochem Biophys Res Commun 191: 503-508, 1993
25. Steven GR: Leishmaniasis vaccination: Targeting the source of infection. J Exp Med 194: 7-10, 2001
26. De Luca PM, Mayrink W, Alves CR, Continho SG, Oliveira MP, Bertho AL, Toledo VP, Costa CA, Genaro O, Mendonca SC: Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17: 1179-1185, 1999
27. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, Dowlati Y, Sharifi I, Aminjavaheri M, Shafiei A, Alimohammadian MH, Hashemi-Fesharki R, Nasseri K, Godal T, Smith PG and Modabber F: A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17: 466-472, 1999
28. Rivier D, Shah R, Bovay P, Manel J: Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol 15: 75-84, 1993
29. Titus RG, Gueiros-Filho FJ, Freitas de LA, Beverley SM: Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 92: 10267-10271, 1995
30. Veras P, Brodskyn C, Balestieri F, Freitas L, Ramos A, Queiroz A, Barral A, Beverley S, Barral-Netto M: A dhfr2ts2 Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo Cruz 94: 491-496, 1999
31. Ramirez JR, Gilchrist K, Robledo S, Sepulveda JC, Moll H, Soldati D, Berberick C: Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. Vaccine 20: 455-461, 2001
32. Russell DG, Alexander J: Effective immunization against cutaneious leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 140: 1274-1279, 1988
33. Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, Koech DK, McMaster WR: Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). Vet Parasitol 60: 199-212, 1995
34. Handman E, Symons FM, Baldnin TM, Curtis JM, Scheerlinck JPY: Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 63: 4261-4267, 1995
35. Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG: LeIF: A recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 161: 6171-6179, 1998
36. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA: Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186: 1137-1147, 1997
37. Strager S, Smith DF, Kayl PM: Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165: 7064-7071, 2000
38. Handman E, Mitchell GF: Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci USA 82: 5910-5914, 1985
39. Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurcha SS, Grant E, Rosat JP, Brenner MB, Costello CE, Besra GS, Porcelli SA: CD1 c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404: 884-888, 2000
40. Spitzer N, Jardim A, Lippert D, Olafson RW: Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 17: 1298-1300, 1999
41. Chicharro C, Granata C, Lozano R, Andreu D, Rivas L: N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a Cecropin-Melittin hybrid peptide. Antimicrob Agents Chemother 45: 2441-2449, 2001
42. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel NA: Protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19: 3369-3375, 2001
43. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, Vogel JC: Genetic immunization with glycoproteins 63 cDNA results in a helper T cell type 1 immune response and protection in a routine model of leishmaniasis. Hum Gene Ther 9: 1899-1907, 1998
44. Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA., Yasir A, Skeiky W, Campos-Neto A, Reed S, Robert A. Seder, Sacks D: The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166: 5122-5128, 2001
45. Streit JA, Recker TJ, Donelson JE, Wilson ME: BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 94: 33-41, 2000
46. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998
47. Celia M, Döhring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Colonna M: A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing J Exp Med 185: 1743-1751, 1997
48. Mellman I, Steinman RM: Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255-258, 2001
49. Blank C, Fuchs H, Rappersberger K, Rollinghoff M, Moll H: Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major. J Infect Dis 167: 418, 1993
50. Moll H, Flohe S, Rollinghoff M: Dendritic cells in Leishmania major-immune mice harbour persistent parasites and mediate an antigen-specific T cell immune response. Eur J Immunol 23: 693, 1995
51. Stebut V, Belkaid EY, Jakob T, Sacks DL, Udey MC: Uptake of Leishmania major amastigotes results in activation and interleukin-12 release from murine skin-derived dendritic cells: Implications for the initiation of anti-Leishmania immunity. J Exp Med 188: 1547-1552, 1998
52. Flohe SB, Bauer C, Flohe S, Moll H: Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 28: 3800, 1998
53. Kremer IB, Gonld MP, Cooper KD, Heinzel FP: Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous Leishmaniasis in susceptible BALB/c mice. Infect Immun 69: 673-680, 2001
54. Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J: Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes. Infect Immun 65: 3386, 1997
55. Messer SR, Whitmire W, Fischer E, Portis JC, Cadwell HD: Vaccination against chlamydial genital tact infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med 188: 809, 1998
56. Bourguin I, Moser M, Buzoni-Gatel D, Tielemans F, Bout D, Urbain J, Leo O: Murine dendritic cells pulsed in vitro with Toxoplasma gondii antigens induce protective immunity in vivo. Infect Immun 66: 4867-4874, 1998
57. +-T-cell epitopes from antigen 85A. Infect Immun 70: 1623-1626, 2002
58. Hernando J, Park TW, Kubler K, Offergeld R, Schlebusch H, Banknecht T: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51: 45-52, 2002
59. Bouloc A, Walker P, Grivel JC, Vogel JC, Katz SI: Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells. Eur J Immunol 29: 446-454, 1999
60. Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, Mathew J, Melby PC, Ahuja SK: Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 163: 3890-3897, 1999
61. Udey MC, VonStebut E, Mendez S, Sacks DC, Belkaid Y: Skin dendritic cells in murine cutaneous Leishmaniasis. Immunobiology 204: 590-594, 2001